Ambiotis

TRANSPHARMATION Ltd is a preclinical CRO spun out of GlaxoSmithKline Pharmaceuticals (GSK) in 2010. Our mission is to be regarded as the leading CRO for cross-species and cross-therapeutic area in translational pharmacology from bench to bedside.

Following the transfer of key personnel, assay know-how and equipment from GSK, TRANSPHARMATION has enjoyed unprecedented growth in its preclinical and experimental medicine service offering.

This growth has been driven by highly characterised assays sensitive to clinical gold standards, state of the art technology and human tissue assays. With models spanning rodents, dogs and non-human primates through to humans, our core therapeutic expertise includes: EEG, cognition (Alzheimer's and Parkinson's disease), epilepsy, pain, neurodegeneration, neuroinflammation and anxiety/mood disorders (including treatment-resistant depression, sleep disorders and schizophrenia), together with a biomarker platform, PD/PK studies and human tissue capabilities.

In addition, Transpharmation has a significant internal research programme centred on a strategy to better understand and stratify responders and non-responders to clinical gold standards based on the detection of neurophysiological and molecular biomarkers.

Transpharmations' HQ is located at The London Bioscience Innovation Centre, and R&D facilities are located at: Building 500, Discovery Park (Kent-UK), Trinity College Dublin - Institute of Neuroscience (Ireland) and Faculty of Veterinary Medicine University of Warmia & Mazury in Olsztyn (Poland).

Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.

Celentyx is a human immune system focused R&D and service company specialising in immuno-oncology, inflammation and autoimmunity in vitro assays using healthy donor and patient tissues and cells.

Celentyx’s unique ImmuKnowlogy™ platform allows rapid analysis of drug action on human immune cells - from healthy donors or patients with defined clinical disease. Drawing on the World-leading expertise of Celentyx personnel, which along with our strategic relationships with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research (at the Queen Elizabeth 'Super-hospital', Birmingham), enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's ImmuKnowlogy™ services enable partners to quantify efficacy, elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

Celentyx's Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to reprofile (repurpose) drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug indications.

Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics.

Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation, infectious diseases, biofilm culture, stem cell research, sickle cell disease, asthma, and allergies. Our Microfluidic Solutions include set-ups for droplet generation, organ-on-chip and VOC analysis.

More recently, Cellix's multi-disciplinary team of engineers and scientists have been developing our Inish Solutions range: microfluidic label-free impedance cell analysis and sorting. We want our customers to succeed so we are demystifying flow cytometry and bringing them simple, easy-to-use cell analysis and sorting for every lab, not just core facilities.